Curcumin, a nonselective Kv1.3 blocker, was first revealed in a mouse model to improve psoriasis lesions and lower inflammatory mediators such as TNF-α, IFN-γ, IL-2, IL-12, IL-22 and IL-23 (49). Here, TNF is linked to psoriasis.